The possible presence of an unknown prostacyclin synthesis inhibitory substance has been reported in some strains of rats. We purified the inhibitory substance from the heart of spontaneously hypertensive rats by collecting active fractions after gel-filtration column chromatography and two steps of reverse-phase high performance liquid chromatography. The amino acid composition and automated gas-phase sequencing of the full-length substance and fragments cleaved by AspN indicated that the prostacyclin-inhibitory peptide was identical to coupling factor 6. Recombinant rat coupling factor 6, which was synthesized using a cleavable fusion protein strategy, attenuated base-line and bradykinin (10 ؊6 M)-induced prostacyclin synthesis and 
M recombinant coupling factor 6 had no influence on adenosine diphosphate-and collagen-induced platelet aggregations. We conclude that coupling factor 6 possesses a novel function of prostacyclin synthesis inhibition in endothelial cells via suppression of Ca 2؉ -dependent cytosolic phospholipase A 2 , although it is unclear whether coupling factor 6 functions in normal conditions or only in pathophysiological states.
Prostacyclin, a potent vasodilator and the most potent endogenous inhibitor of platelet aggregation known, is synthesized from arachidonic acid (AA) 1 by various stimuli in many types of cells, including vascular endothelial cells and smooth muscle cells. Of a number of stimuli, bradykinin (1, 2) and arginine vasopressin (3) , whose receptors are coupled to GTPbinding proteins, enhance AA release via Ca 2ϩ -dependent translocation of cytosolic phospholipase A 2 (PLA 2 ) (4) and the activation of PLA 2 due to phosphorylation (5, 6) . In contrast, growth factors (7, 8) , whose receptors are coupled to tyrosine kinase, activate PLA 2 by the additional mechanism of de novo protein synthesis. A novel substance, designated prostacyclinstimulating factor (9) , has recently been discovered to be a stimulus for AA release, and the physiological and pathophysiological roles of this new substance in health and disease are being investigated.
The in vivo function of endogenous prostacyclin was unknown until quite recently. Mice lacking the gene for encoding the prostacyclin receptor (10) , which was cloned from a human lung library (11) , demonstrated increased susceptibility to thrombosis, reduced pain perception, and decreased inflammatory response. These functions seem to be related to the amount of prostacyclin, which is regulated not only by stimuli that augment synthesis but also by the clearance from the circulating system and synthesis inhibitors. A prostaglandin (PG) transporter (12) , which was isolated from the protein encoded by the rat matrin complementary DNA, mediates the vascular clearance of classical PGs on passage through the pulmonary circulation but does not mediate the clearance of prostacyclin. Thus, it could not contribute to the regulation of prostacyclin effects. On the other hand, lipomodulin or macrocortin (13) (14) (15) , which is known to be an inhibitory protein of PLA 2 , inhibits the inflammatory effect of prostacyclin, but it is limited only when anti-inflammatory glucocorticoids were administered and only to the inside of the cell.
In recent years, exposure to a high salt diet has been reported to increase the plasma concentration of an unknown substance that inhibits AA release from the plasma membrane in Dahl salt-sensitive rats (16) and Wistar rats (17) . In addition, urinary excretion of 2,3-dinor-6-keto-PGF 1␣ , an indicator for endogenous prostacyclin levels, was demonstrated to be similar in both spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto rats, despite the enhanced activity of prostacyclin synthesis in SHR-derived aortic strips (18, 19) . Thus, these lines of accumulating evidence strongly suggest that there may be undiscovered endogenous prostacyclin synthesis inhibitor(s). Based on this reasoning, we tried to isolate and identify the prostacyclin synthesis inhibitory substance(s) by using SHR, which appear to be a suitable source for isola-* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ To whom correspondence should be addressed: Second -dependent cytosolic PLA 2 inhibitor) was purchased from Biomol. PGH 2 , oleyloxyethyl phosphorylcholine (OPC; Ca 2ϩ -dependent secretory PLA 2 inhibitor), and bromoenol lactone (BEL; Ca 2ϩ -independent cytosolic PLA 2 inhibitor) were purchased from Cayman Chemicals, Ann Arbor, MI. Ionomycin was from Calbiochem. Cell culture media were purchased from Life Technologies, Inc., except that HuMedia was from Kurabou, Osaka, Japan. EcoRI, SalI, and T4 DNA ligase were purchased from Takarashuzo, Kyoto, Japan. All other reagents were of the finest grade available from Sigma.
Isolation and Determination of Prostacyclin Synthesis Inhibitory Substance-Brain, heart, lung, kidney, liver, and intestine obtained from 10 SHR were heat-treated in boiling water for 10 min and extracted with 1 M acetic acid (AcOH). After desalting through a Sep-Pak C 18 column, followed by acetone precipitation at a concentration of 66%, the resulting supernatant was then evaporated in vacuo to dryness. The inhibitory activity of each crude extract was determined by measuring the amount of 6-keto-PGF 1␣ released from vascular smooth muscle cells exposed to the extract, by using the following method. Vascular smooth muscle cells were isolated from the mesenteric arteries of SHR and were grown to subconfluence on 24-well plates in 10% fetal bovine serum, Dulbecco's modified Eagle's medium (DMEM). The cells were washed twice with serum-free DMEM and incubated in 250 l of serumfree DMEM in the presence or absence of crude extract (10 g protein/ ml) at 37°C. After 30 min, the medium was collected and the concentration of 6-keto-PGF 1␣ was measured by direct radioimmunoassay in duplicate, as reported previously (20) .
Next, the dry material of 187 SHR hearts, extracted by the same procedure exactly, was dissolved in 1 M AcOH, subjected to a column of Sephadex G-25 (1.5 ϫ 30 cm) at 3 ml/h flow rate, and collected into 0.5-ml/tube fractions. The active fraction (number 19 -21) from the gel-filtration column chromatography was applied on reverse-phase high performance liquid chromatography (HPLC) using an Inertsil ODS-2 C18 column (4.6 ϫ 250 mm, GL Science Inc.) and an acetonitrile/ 0.05% trifluoroacetic acid elution at 10% acetonitrile over the first 10 min and followed by linear gradient of acetonitrile ranging from 10 to 50% over 40 min at 1 ml/min flow rate. The active fraction shown with a black bar was further subjected to an ODS-80A C18 column (4.6 ϫ 250 mm, GL Science Inc.) and an acetonitrile, 0.05% trifluoroacetic acid elution at 20% acetonitrile over the first 5 min followed by linear gradient of acetonitrile ranging from 20 to 60% over 30 min with a flow rate of 1 ml/min, and eventually purified as a single peptide peak. The amino acid composition of the purified peptide was determined by amino acid analyzer (JLC-300, Japan) after hydrolysis of the peptide in 6 N HCl containing 0.005% phenol at 110°C for 20 h. The amino acid sequence of the purified full-length peptide was first analyzed by automated gas-phase peptide sequencing. Next, after 1.6 g of the peptide was digested with 36 ng of AspN (endopeptidase) in 89 l of 1 M urea (pH 8.0) containing 200 mM tetrahydrobiopterin at 37°C for 6 h, the peptide fragments were separated by reverse-phase HPLC using YMC A-302 (4.6 ϫ 150 mm). Elution was carried out with a linear gradient of 0 -80% acetonitrile in a 0.1% trifluoroacetic acid solution at a flow rate of 1 ml/min for 80 min. The amino acid sequence of the peptide fragments was then determined by the same procedure.
Synthesis of Recombinant Coupling Factor 6 -Recombinant rat coupling factor 6, to which the prostacyclin synthesis inhibitory peptide was found to be identical, was synthesized and provided by Suntory Institute for Biomedical Research, Japan. Briefly, recombinant coupling factor 6 was obtained from Escherichia coli using a cleavable fusion protein strategy (21) . Chemically synthesized rat coupling factor 6 gene, which possesses DNA fragment encoding the factor Xa recognition peptide sequence (EFGLIEGR) in the upstream, was ligated to the EcoRI-and SalI-digested pG97S4DhCT [G] plasmid (22) with T4 DNA ligase. E. coli JM109 cells harboring the constructed plasmid were grown at 37°C for 16 h in 100 ml of SB medium composed of 0.27% yeast, 0.12% (NH 4 ) 2 SO 4 , 0.02% NH 4 Cl, 2 mg/ml L-methionine, 0.2% MgSO 4 -7H 2 O, and the mineral solution reported previously (23) . E. coli cells that had been cultured as just described were collected and mechanically disrupted with the Manton-Ganllin homogenizer (model 15M8TBA) at a pressure of 500 kg/cm 2 . The inclusion bodies were collected by centrifugation and washed twice with deionized water. The washed inclusion bodies were then suspended in 2 M urea solution (50 mM Tris-HCl at pH 8.0, 100 mM NaCl, and 2 mM CaCl 2 ). After preincubating at 30°C for 10 min, factor Xa was added to the solution at an enzyme/substrate ratio of 1:600 (w/w), which was then incubated for 120 min. Cleaved rat coupling factor 6 was purified by HPLC using YMC A-302 (4.6 ϫ 150 mm). Elution was carried out with a linear gradient of 25.5-47.2% acetonitrile in a 0.1% trifluoroacetic acid solution at flow rate of 1 ml/min for 54 min. Finally, the amino acid sequence and molecular mass of this recombinant peptide were checked by automated gas-phase peptide sequencing and mass spectrometry.
Effects of Recombinant Coupling Factor 6 on Prostacyclin Synthesis-Dose-dependent effects of recombinant coupling factor 6 (10 Ϫ9 -10 Ϫ7 M) on base line and bradykinin (10 Ϫ6 M)-induced prostacyclin production were assessed by measuring the amount of 6-keto-PGF 1␣ released from subconfluent human umbilical vein endothelial cells (HUVEC) on 24-well plates for 30 min. Briefly, HUVEC were grown to subconfluence on 24-well plates in complete medium (HuMedia) supplemented with 2% fetal bovine serum, 10 ng/ml recombinant epidermal growth factor, 1 g/ml hydrocortisone, 5 ng/ml recombinant basic fibroblast growth factor, and 10 g/ml heparin. The cells were washed twice with 700 l of serum-free DMEM and incubated with various concentrations of coupling factor 6 in the absence or presence of 10 Ϫ6 M bradykinin in 250 l of serum-free DMEM for 30 min at 37°C. To determine the site of action of coupling factor 6, the effects of this recombinant peptide at 10 Ϫ7 M on conversion of both exogenous AA (10 ng/ml) to prostacyclin and exogenous PGH 2 (10 ng/ml) to prostacyclin were assessed by the same method. In addition, prostacyclin synthesis due to calcium-dependent PLA 2 activation was measured after the addition of ionomycin (2 g/ml) in both the absence and presence of coupling factor 6.
Effects of Recombinant Coupling Factor 6 on AA Release-HUVEC were grown to subconfluence on 24-well plates in the complete medium. The cells were then labeled for 24 h with [
3 H]AA (0.25 Ci in 250 l of complete medium/well at 37°C), washed twice with 700 l of serumfree DMEM, and preincubated for 10 min in the same medium. This medium was removed, and the cells were incubated with various concentrations of coupling factor 6 in both the absence and presence of 10
Ϫ6
M bradykinin in 250 l of serum-free DMEM at 37°C. In some experiments, the cells were incubated with AACOCF 3 at 40 M, OPC at 1 M, or BEL at 1 M in both the absence and presence of 10 Ϫ6 M bradykinin. After 30 min, the medium was collected and the 3 H level was counted with a liquid scintillation counter. In addition, the effect of co-administration of coupling factor 6 at 10 Ϫ7 M and AACOCF 3 was also assessed by the same method.
Effects of Recombinant Coupling Factor 6 on Platelet FunctionPlatelets were harvested as described previously (24) . Briefly, plateletrich plasma was prepared from SHR by centrifugation of blood samples containing 10% sodium citrate at 190 ϫ g for 7 min and platelet-poor plasma by centrifugation of platelet-rich plasma at 900 ϫ g for another 10-min period at room temperature. Platelet aggregation in plateletrich plasma was examined with an aggregometer (NKK hemotracer 1, Japan) in siliconized cuvettes with continuous stirring at 37°C. Platelet aggregation was induced with 2.5 or 5 M adenosine diphosphate (ADP) and 0.5 g/ml collagen after pretreatment with 10 Ϫ7 M recombinant coupling factor 6 for 1 min, and the maximum aggregability was obtained.
Statistics-All data are shown as mean Ϯ 1 S.E. An unpaired t test for comparison of two variables and analysis of variance for repeated measures for multiple comparison were used for statistical analysis. The level of significance was Ͻ0.05.
RESULTS

Purification and Determination of Prostacyclin Synthesis
Inhibitory Peptide-As shown in Fig. 1a, 6 -keto-PGF 1␣ production was most strongly suppressed by the heart extract, and its suppression was abolished by pretreatment with trypsin and chymotrypsin (data not shown). Therefore, the prostacyclininhibitory peptide was purified from 187 hearts (152 g) of SHR by collecting active fractions after gel-filtration column chromatography (Fig. 1b) . The fraction numbers 19 -21 that are approximately equivalent to relative molecular mass 9000 Da showed the highest inhibitory activity. Thus, after being evaporated in vacuo to dryness, the active fraction was applied to two steps of reverse-phase HPLC (Fig. 1, c and d ) and eventu-ally purified as a single peak. Purity of the single peak (9.5 g) eluted from the final HPLC (Fig. 1d) was verified by reversephase HPLC with different kinds of elution and by gel electrophoresis. The amino acid composition, determined by acid hydrolysis, was (mol/mol of peptide) as follows: Asx, 9.4; Ser, 2.2; Glx, 13.3; Val, 4.3; Met, 2.3; Ile, 1.0; Leu, 6.6; Tyr, 2.8; Phe, 6.2; Lys, 10.8; Thr, 1.9; Arg, 3.3; Gly, 5.1; Pro, 6.3; Ala, 2.2. His, Cys and Trp were undetected. Automated gas-phase peptide sequencing of the purified full-length peptide (Fig. 1e) was interpretable up to the 40th amino acid from the N terminus and was completely identical to coupling factor 6.
Four of the 8 fragment peptides cleaved by AspN were found to have amino acid sequences compatible with the amino acid sequence up to the 39th described above. The sequences of the other four fragments were DRELFKLKQMYGKGEM, DKFPT-FNFE, DPKFEVL, and DKPQS, which were completely identical to the 40 -55th, the 56 -64th, the 65-71st, and the 72-76th amino acid sequences of rat coupling factor 6, respectively. These results indicated that the prostacyclin-inhibitory peptide was of relative molecular mass 9000 Da, comprised of 76 amino acid residues, and identical to coupling factor 6.
Effects of Recombinant Coupling Factor 6 on Prostacyclin Synthesis-Prostacyclin synthesis at base line was 234 Ϯ 36 pg/well/30 min in HUVEC. As shown in Fig. 2 , recombinant coupling factor 6 suppressed it in a dose-dependent manner (10 Ϫ9 -10 Ϫ7 M). Treatment with bradykinin at 10 Ϫ6 M elicited an increase in prostacyclin synthesis from 272 Ϯ 45 to 469 Ϯ 24 pg/well/30 min (Fig. 3) . Simultaneous administration of coupling factor 6 suppressed bradykinin-induced prostacyclin production in a dose-dependent manner. Ionomycin-induced increase in prostacyclin production above the base line was suppressed from 857 Ϯ 9 to 683 Ϯ 23 pg/well/30 min (n ϭ 4, p Ͻ 0.05) by recombinant coupling factor 6 at 10 Ϫ7 M. In contrast, exogenous AA-induced increase in prostacyclin synthesis above (Fig. 7) . The addition of coupling factor 6 at 10 Ϫ7 M to AACOCF 3 at 40 M showed no further suppressant effect on the [ 3 H]AA release induced by bradykinin (555 Ϯ 26 cpm/well/30 min).
Effects of Recombinant Coupling Factor 6 on Platelet Function-ADP at 2.5 and 5 M and collagen at 0.5 g/ml all induced significant platelet aggregation. The maximum aggregation was 30 Ϯ 1% with 2.5 M ADP, 39 Ϯ 1% with 5 M ADP, and 63 Ϯ 8% with collagen. Preincubation (1 min) with 10 Ϫ7 M of recombinant coupling factor 6 had no influence on ADP (2.5 and 5 M)-and collagen-induced maximum platelet aggregation (2.5 M of ADP, 30 Ϯ 1% (n ϭ 3); 5 M of ADP, 40 Ϯ 3% (n ϭ 3); collagen, 63 Ϯ 5% (n ϭ 3)).
DISCUSSION
In the present study, a prostacyclin synthesis inhibitory substance was purified from the heart of SHR, and its structure was determined. It was a 76-amino acid peptide, and the sequence from the N terminus to the 40th amino acid was completely identical to the known peptide designated coupling factor 6. Further analysis of fragment peptides cleaved by AspN revealed that the amino acid sequences of the initial four fragments were identical to the 1-39th sequences and the other four to the 40 -55th, the 56 -64th, the 65-71st, and the 72-76th sequences of rat coupling factor 6. Thus, the purified peptide was completely identical to rat coupling factor 6. Then, we reconstructed rat coupling factor 6 using a cleavable fusion protein strategy and confirmed the effect of this recombinant peptide on prostacyclin synthesis. Recombinant coupling factor 6 manifested the same effect as the purified substance, and prostacyclin synthesis inhibitory substance was verified as identical to coupling factor 6.
Coupling factor 6 (25) is known to act inside the cell as an energy transducer in mitochondrial adenosine triphosphate synthase that consists of three domains, namely the extrinsic and intrinsic membrane domains, F 1 and F 0 , respectively, joined by a stalk. F 0 is the proton channel of the complex that spans the inner mitochondrial membrane, and the protons are conducted from F 0 through the stalk to the catalytic sites in F 1 composed of five kinds of polypeptides (26, 27) . Four subunits of the stalk have been identified and designated as follows: the oligomycin sensitivity conferral protein, coupling factor 6, and subunit b and d (28 -30) , of which coupling factor 6 is reported to be essentially required for energy transduction (25) . Coupling factor 6 is first synthesized as an immature form in the cytosol, then led to the mitochondria by an import signal peptide (32 amino acids) present in the upstream (31) , and then becomes an active form by the enzymatic deletion of the signal peptide. In the present study, we discovered a novel function of this peptide, an inhibitory effect on prostacyclin synthesis. This effect was demonstrated when the peptide was administered from the outside of the cell. Therefore, after organ damage such as myocardial infarction and myocarditis, this peptide may exert its inhibitory effect on prostacyclin synthesis. The questions whether coupling factor 6, a mitochondrial integral peptide, reaches an appropriate site of action in normal conditions and how coupling factor 6 contributes to the regulation of prostacyclin production in SHR remain to be elucidated.
It is of interest to speculate the site of action of coupling factor 6. Because this peptide attenuated the use of endogenous AA in prostacyclin synthesis without affecting the uses of exogenous AA and PGH 2 , its effect appeared to be focused on PLA 2 (36, 37) . However, BEL has been found to block Mg 2ϩ -dependent phosphatidate phosphohydrolase, a key enzyme in cellular phospholipid metabolism (38) . Base-line and bradykinin-induced AA releases were both suppressed by AACOCF 3 but not by OPC (sPLA 2 inhibitor) and BEL, suggesting that cPLA 2 contributes to AA release under these conditions. Coupling factor 6 suppressed base-line and bradykinin-induced AA releases, and the simultaneous administration of AACOCF 3 and coupling factor 6 had no additive effect to that by AACOCF 3 , suggesting that coupling factor 6 inhibits AA release from the plasma membrane via suppression of cPLA 2 activity.
A distinct difference in the responsiveness to coupling factor 6 was clearly observed between endothelial cells and platelets. We demonstrated that the acting site of coupling factor 6 was AA release from the plasma membrane and not prostacyclin synthase. Therefore, it is reasonable to presume that this peptide may inhibit thromboxane A 2 synthesis in platelets and suppress aggregation of platelets. However, pretreatment of platelets with coupling factor 6 had no influence on the maximum value of platelet aggregation. This lack of effect suggests that coupling factor 6 may exert an AA release-inhibitory effect with cell specificity. Thus, the major PG suppressed by coupling factor 6 is prostacyclin. The mechanism for the cell specificity of the suppressant effect of coupling factor 6 is unknown. However, if coupling factor 6 indirectly inhibits cPLA 2 via mediators such as receptors, one possible reason may be the presence or absence of its mediator(s) in the cell.
Because prostacyclin receptor is expressed in many tissues such as aorta, lung, atrium, ventricle, and kidney (20) , and because PG transporter (12) does not mediate the vascular clearance of prostacyclin, the endogenous prostacyclin synthe- sis inhibitory peptide may have inhibitory effects against widespread biological actions of prostacyclin. This peptide also may counteract a biological action of AA such as inhibition of voltage-gated Ca 2ϩ current, because a major acting site of coupling factor 6 is the inhibition of AA release from the plasma membrane. Further investigations, especially on the in vivo effects of exogenous coupling factor 6, will be required to establish the effect and role of this peptide.
